Genetic causes of sex differentiation abnormalities in males with normal testosterone level: role of androgen receptors

by R. E. Kazakov, R. V. Rozhivanov, E. V. Shikh
Published 2019-04-01

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA

by D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
Published 2015-09-01

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA

by D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
Published 2015-09-01

PHARMACOGENETICS OF ORGANIC CATION TRANSPORTERS

by V. A. Evteev, R. E. Kazakov, O. A. Muslimova, E. Yu. Demchenkova
Published 2018-06-01

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy

by N A Rumyantsev, V G Kukes, R E Kazakov, A A Rumyantsev, D A Sychev
Published 2017-01-01

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANE...

by K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev
Published 2015-09-01

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANE...

by K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev
Published 2015-09-01

Activity of renal organic anion transporters in a model of ischemia and reperfusion injury in vitro

by V. A. Evteev, R. E. Kazakov, A. B. Prokof'ev, I. A. Mazerkina, N. D. Bunyatyan
Published 2018-12-01

Prospects of using C3435T polymorphism in the <i>ABCB1</i> gene encoding P-glycoprotein in personalised medicine

by R. E. Kazakov, V. A. Evteev, O. V. Muslimova, I. A. Mazerkina, E. Yu. Demchenkova, E. V. Shikh
Published 2018-02-01

Organic anion transporters and their influence on the toxicity of β-lactam antibiotics

by V. A. Evteev, O. V. Muslimova, I. A. Mazerkina, N. D. Bunyatyan, E. V. Shikh, R. E. Kazakov
Published 2018-02-01

CYTOCHROME P450 (CYP2C9) ACTIVENESS, EVALUATED VIA LOSARTAN TEST, AS PREDICTION MARKER FOR THE WARFARIN TREATMENT DOSAGE CHOICE IN PATIENTS WITH DELAYED OUTCOMES AFTER HEART VALVES...

by S. M. Arslanbekova, D. A. Sychev, K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, N. M. Magomedova, E. Z. Golukhova
Published 2015-10-01

Pharmacogenetic testing in the treatment of type 2 diabetes with sulfonylurea drugs

by G. I. Gorodetskaya, V. G. Kukes, S. A. Belkov, R. E. Kazakov, S. Yu. Serebrova, O. V. Muslimova, T. A. Rodina, A. A. Aleksandrov
Published 2018-02-01